Caught Between Two Partners: Amylin Seeks To Block Lilly's Byetta Sales Force From Marketing Tradjenta
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin claims Lilly has breached its agreement to commercialize exenatide as the Big Pharma gears up to launch the Boehringer-developed diabetes drug Tradjenta.